High-Throughput Cell-Based Screening of 4910 Known Drugs and Drug-like Small Molecules Identifies Disulfiram as an Inhibitor of Prostate Cancer Cell Growth
暂无分享,去创建一个
O. Kallioniemi | K. Iljin | P. Kohonen | R. Grafström | P. Halonen | P. Vainio | M. Perälä | K. Ketola | V. Fey
[1] J. Błasiak,et al. Zinc salts differentially modulate DNA damage in normal and cancer cells , 2009, Cell biology international.
[2] R. Mumper,et al. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. , 2009, Cancer treatment reviews.
[3] O. Kallioniemi,et al. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG‐positive prostate cancer , 2008, International journal of cancer.
[4] E. Diamandis,et al. High-Throughput Screening Identifies Cardiac Glycosides as Potent Inhibitors of Human Tissue Kallikrein Expression: Implications for Cancer Therapies , 2008, Clinical Cancer Research.
[5] J. Trachtenberg,et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer , 2007, British Journal of Cancer.
[6] K. Pienta,et al. The evolving biology and treatment of prostate cancer. , 2007, The Journal of clinical investigation.
[7] S. Dhanasekaran,et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.
[8] G. Jenster,et al. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. , 2006, Cancer research.
[9] Q Ping Dou,et al. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. , 2006, Cancer research.
[10] O. Kallioniemi,et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. , 2006, Cancer research.
[11] Wolfgang Huber,et al. Analysis of cell-based RNAi screens , 2006, Genome Biology.
[12] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[13] V. Rotter,et al. hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. , 2006, Cancer research.
[14] M. Lei. The MCM complex: its role in DNA replication and implications for cancer therapy. , 2005, Current cancer drug targets.
[15] Z. Sauna,et al. Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections. , 2005, Molecular bioSystems.
[16] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[17] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[18] D. Dréau,et al. Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. , 2004, Molecular cancer therapeutics.
[19] Gordon K Smyth,et al. Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .
[20] Bert Gunter,et al. Improved Statistical Methods for Hit Selection in High-Throughput Screening , 2003, Journal of biomolecular screening.
[21] C. Korch,et al. Molecular characterization of human prostate carcinoma cell lines , 2003, The Prostate.
[22] Brad T. Sherman,et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.
[23] B. Kim,et al. Monensin-mediated growth inhibition in NCI-H929 myeloma cells via cell cycle arrest and apoptosis. , 2003, International journal of oncology.
[24] H. McLeod,et al. Disulfiram‐mediated inhibition of NF‐κB activity enhances cytotoxicity of 5‐fluorouracil in human colorectal cancer cell lines , 2003, International journal of cancer.
[25] Joon-Oh Park,et al. Monensin inhibits the growth of renal cell carcinoma cells via cell cycle arrest or apoptosis. , 2003, International journal of oncology.
[26] B. Kim,et al. Monensin-mediated growth inhibition of SNU-C1 colon cancer cells via cell cycle arrest and apoptosis. , 2003, International journal of oncology.
[27] Y. Im,et al. Monensin‐mediated growth inhibition in human lymphoma cells through cell cycle arrest and apoptosis , 2002, British journal of haematology.
[28] M. Marikovsky. Thiram inhibits angiogenesis and slows the development of experimental tumours in mice , 2002, British Journal of Cancer.
[29] J. Yakisich,et al. Disulfiram is a potent in vitro inhibitor of DNA topoisomerases. , 2001, Biochemical and biophysical research communications.
[30] K. Pienta,et al. VCaP, a cell-based model system of human prostate cancer. , 2001, In vivo.
[31] L. Nutt,et al. Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. , 2000, Cancer research.
[32] J. Stanford,et al. Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[33] R. Franklin,et al. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer , 1998, The Prostate.
[34] M. Webber,et al. Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells. , 1997, Carcinogenesis.
[35] J. Moul,et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. , 1994, Cancer research.
[36] H. Mollenhauer,et al. Alteration of intracellular traffic by monensin; mechanism, specificity and relationship to toxicity , 1990, Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes.
[37] K. Toyoda,et al. Carcinogenicity study of tetramethylthiuram disulfide (thiram) in F344 rats. , 1988, Toxicology.
[38] T. Ozawa,et al. Neutrophils biosynthesize leukotoxin, 9, 10-epoxy-12-octadecenoate. , 1986, Biochemical and biophysical research communications.
[39] P. Peters,et al. Neurotoxicity and behavioral effects of thiram in rats. , 1976, Environmental health perspectives.
[40] J. Gower. Some distance properties of latent root and vector methods used in multivariate analysis , 1966 .
[41] O. Linton. Local Regression Models , 2010 .
[42] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[43] Justin Lamb,et al. The Connectivity Map: a new tool for biomedical research , 2007, Nature Reviews Cancer.
[44] Anders Isaksson,et al. Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients. , 2007, Biochemical pharmacology.